XBIOTECH INC. (XBIT)
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
📈 **POSITIVE** • Low confidence analysis (42%) • Moderate positive clinical data • Good growth prospects **Sentiment:** Positive (55%) **Content type:** Clinical